Compare TTI & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTI | SLDB |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1996 | 2017 |
| Metric | TTI | SLDB |
|---|---|---|
| Price | $7.17 | $49.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $10.40 | ★ $16.36 |
| AVG Volume (30 Days) | ★ 1.9M | 876.6K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $4.70 | N/A |
| Revenue Next Year | $11.35 | N/A |
| P/E Ratio | $52.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.44 | $3.79 |
| 52 Week High | $12.54 | $11.45 |
| Indicator | TTI | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 31.37 | 56.51 |
| Support Level | N/A | $5.21 |
| Resistance Level | $8.99 | $11.45 |
| Average True Range (ATR) | 0.37 | 0.43 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 7.47 | 67.25 |
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments, namely Completion Fluids & Products and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. The Water & Flowback Services Segment provides onshore oil and gas operators with comprehensive water management services. The majority of revenue is from the Completion Fluids & Products segment.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.